FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
ALLOS THERAPEUTICS INC [ (ALTH) ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 01/29/2002 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock(1) | 11/19/2002 | P | 900(2) | A | $7.6856 | 5,074,670(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/20/2002 | P | 2,300(2) | A | $7.7235 | 5,076,970(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/20/2002 | P | 2,100(2) | A | $7.7192 | 5,079,070(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/20/2002 | P | 2,500(2) | A | $8.2 | 5,081,570(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/21/2002 | P | 7,150(2) | A | $8.0445 | 5,088,720(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/21/2002 | P | 500(2) | A | $8.185 | 5,089,220(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/21/2002 | P | 3,800(2) | A | $8.0468 | 5,093,020(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/22/2002 | P | 600(2) | A | $7.84 | 5,093,620(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/22/2002 | P | 500(2) | A | $7.96 | 5,094,120(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/26/2002 | P | 468(2) | A | $7.985 | 5,094,588(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/26/2002 | P | 1,100(2) | A | $8.015 | 5,095,688(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/27/2002 | P | 500(2) | A | $8.015 | 5,096,188(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/27/2002 | P | 700(2) | A | $8.0086 | 5,096,888(2) | I | See Footnote(3) | ||
Common Stock(1) | 11/29/2002 | P | 700(2) | A | $7.9943 | 5,097,588(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/02/2002 | P | 3,000(2) | A | $8.035 | 5,100,588(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/02/2002 | P | 2,700(2) | A | $7.9459 | 5,103,288(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/02/2002 | P | 1,800(2) | A | $8.0228 | 5,105,088(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/03/2002 | P | 9,250(2) | A | $7.7512 | 5,114,338(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/03/2002 | P | 10,000(2) | A | $7.65 | 5,124,338(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/03/2002 | P | 10,000(2) | A | $7.6475 | 5,134,338(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/03/2002 | P | 5,000(2) | A | $7.615 | 5,139,338(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/03/2002 | P | 19,400(2) | A | $7.7106 | 5,158,738(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/04/2002 | P | 1,950(2) | A | $7.5653 | 5,160,688(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/04/2002 | P | 100(2) | A | $7.515 | 5,160,788(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/05/2002 | P | 3,950(2) | A | $7.5643 | 5,164,738(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/05/2002 | P | 7,500(2) | A | $7.5 | 5,172,238(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/05/2002 | P | 7,000(2) | A | $7.5486 | 5,179,238(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/06/2002 | P | 28,700(2) | A | $7.4383 | 5,207,938(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/06/2002 | P | 5,300(2) | A | $7.4998 | 5,213,238(2) | I | See Footnote(3) | ||
Common Stock(1) | 12/09/2002 | P | 2,050(2) | A | $7.3385 | 5,215,288(2) | I | See Footnote(3) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
Explanation of Responses: |
1. This Form 4 is being filed by Durus Capital Management, LLC ("Capital") and Scott Sacane. Because the SEC's electronic filing system does not allow for the disclosure of more than 30 transactions on one Form 4, the Reporting Persons are filing 25 simultaneous Form 4s to report their reportable transactions all of which together shall be deemed a single report filed on this date. This is the 16th Form 4 of the 25 filings. |
2. In accordance with instruction 4(b)(iv) of Form 4, these amounts reflect the aggregate amount of shares controlled by Capital (and by Scott Sacane through Capital) under Section 13(d) of the Exchange Act. Each Reporting Person disclaims beneficial ownership under Section 16 of the Exchange Act with respect to such transactions or securities, as applicable, to the extent greater than their indirect pecuniary interest therein. |
3. Through Durus Life Sciences Master Fund Ltd. |
/s/ Scott Sacane | 08/22/2003 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |